Although it has been possible to obtain a prescription for cannabis medicines in Switzerland for a number of years, it is not uncommon for patients to incur considerably higher costs than if they were to obtain cannabis products on the black market. Prof. Dr. med. Reto Auer, Bern Institute of Family Medicine, explained the nature of this dilemma in his presentation.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Pelargonium sidoides
Scoping review sheds light on the multifaceted spectrum of effects
- New evidence on genetics, pathophysiology and clinical significance
Migraine with and without aura – two different entities?
- Prevention of skin cancer
UV protection and skin cancer screening – Update 2025
- Case report: L. pneumophila pneumonia
Negative test results – but no alternative diagnoses
- Clinical case reports and implications for GP care
Magnesium deficiency and dilated cardiomyopathy in the peripartum context
- SID Annual Meeting: Highlights
Update on inflammatory dermatoses – a concentrated load of innovative power
- Case series
Bleeding prophylaxis for von Willebrand disease
- A critical analysis of the evidence from 113 studies